MTB C VACCINE AGAINST ASTHMA

The invention relates to an agent for the treatment or prevention of an allergic condition such as asthma in a mammal. The agent comprises fragments of a complex (MTB C) strain. These particular fragments may be from a virulent MTB C strain and/or in the form of a liposome composition. The agent may...

Full description

Saved in:
Bibliographic Details
Main Authors AMAT FABREGAT MARIA MERCÈ, CARDONA IGLESIAS PERE JOAN, AMAT RIERA ISABEL, REYES MORENO BLANCA
Format Patent
LanguageEnglish
Published 08.05.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to an agent for the treatment or prevention of an allergic condition such as asthma in a mammal. The agent comprises fragments of a complex (MTB C) strain. These particular fragments may be from a virulent MTB C strain and/or in the form of a liposome composition. The agent may include further components such as a liposome forming agent and/or particular proteins from the MTB C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.
Bibliography:Application Number: IN2014MUMNP1594